Amarantus BioScience Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMBS research report →
Price Chart
About the company
Amarantus BioScience Holdings, Inc. operates as a biopharmaceutical firm, concentrating on creating innovative diagnostic tools and therapeutic solutions. Its primary focus areas encompass neurological disorders, psychiatric conditions, eye-related ailments (ophthalmology), and regenerative medicine.
- CEO
- John Wesley Commissiong
- IPO
- 2010
- Employees
- 12
- HQ
- New York City, NY, US
Get TickerSpark's AI analysis on AMBS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $36.84K
- P/E
- -0.01
- PEG
- -0.00
- P/S
- 0.39
- P/B
- -0.00
- EV/EBITDA
- -4.23
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -281.13%
- Net Margin
- -4995.23%
- ROE
- 21.36%
- ROIC
- 4.85%
Latest fiscal year · YoY change
- Revenue
- $95.33K+0.0%
- Gross Profit
- $95.33K+0.0%
- Op Income
- $-268,000
- Net Income
- $-4,762,000+53.3%
- EPS
- $-0.01+62.6%
- OCF Growth
- +54.7%
- FCF Growth
- +54.7%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -4.74
- RSI (14)
- 44
- Avg Volume
- 196.89K
No earnings-call transcripts are available for AMBS yet.
- Free Float
- 100.0%
- Shares Outstanding
- 368.41M
- Float Shares
- 368.41M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 17 | Wei Rongguo | other | 0 |
| May 12, 17 | Flanigan Conn | other | 0 |
| May 3, 17 | TRAPP ROBERT H | other | 0 |
| Feb 23, 17 | Spence Steven | other | 0 |
| Feb 23, 17 | TRAPP ROBERT H | other | 0 |
| Feb 23, 17 | Flanigan Conn | other | 0 |
| Feb 23, 17 | Wei Rongguo | other | 0 |
| Feb 1, 16 | COMMISSIONG GERALD | other | 45,283 |
| Dec 2, 15 | HARRIS ROBERT LEWIS | buy | 19,500 |
| Apr 9, 15 | FARRELL ROBERT EDWARD | buy | 200,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMBS coverage
Recent articles, reports, and earnings notes.
No research on AMBS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMBS report →Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
defenseworld.net · Mar 15
Contrasting Amarantus Bioscience (OTCMKTS:AMBS) & Progyny (NASDAQ:PGNY)
defenseworld.net · Feb 9
Contrasting Pediatrix Medical Group (NYSE:MD) & Amarantus Bioscience (OTCMKTS:AMBS)
defenseworld.net · Dec 31
Head to Head Comparison: Amarantus Bioscience (OTCMKTS:AMBS) & PACS Group (NYSE:PACS)
defenseworld.net · Dec 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.